145 related articles for article (PubMed ID: 7909491)
1. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
[TBL] [Abstract][Full Text] [Related]
2. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma.
Pisani AL; Barbuto DA; Chen D; Ramos L; Lagasse LD; Karlan BY
Obstet Gynecol; 1995 May; 85(5 Pt 1):729-34. PubMed ID: 7724103
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu expression: a major prognostic factor in endometrial cancer.
Hetzel DJ; Wilson TO; Keeney GL; Roche PC; Cha SS; Podratz KC
Gynecol Oncol; 1992 Nov; 47(2):179-85. PubMed ID: 1361478
[TBL] [Abstract][Full Text] [Related]
7. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression.
Nazeer T; Ballouk F; Malfetano JH; Figge H; Ambros RA
Am J Obstet Gynecol; 1995 Dec; 173(6):1829-34. PubMed ID: 8610771
[TBL] [Abstract][Full Text] [Related]
8. Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer.
Nagai N; Oshita T; Fujii T; Kioka H; Katsube Y; Ohama K
Oncol Rep; 2000; 7(3):551-9. PubMed ID: 10767367
[TBL] [Abstract][Full Text] [Related]
9. Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFr--a survival study.
Layfield LJ; Thompson JK; Dodge RK; Kerns BJ
J Surg Oncol; 1995 May; 59(1):21-7. PubMed ID: 7745972
[TBL] [Abstract][Full Text] [Related]
10. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
11. Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma.
Bell JG; Minnick A; Reid GC; Judis J; Brownell M
Gynecol Oncol; 1997 Sep; 66(3):388-92. PubMed ID: 9299250
[TBL] [Abstract][Full Text] [Related]
12. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
13. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.
Reinartz JJ; George E; Lindgren BR; Niehans GA
Hum Pathol; 1994 Oct; 25(10):1075-83. PubMed ID: 7927313
[TBL] [Abstract][Full Text] [Related]
14. Expression of Her-2/neu oncogene protein product and epidermal growth factor receptors in surgical specimens of human breast cancers.
Moe RE; Moe KS; Porter P; Gown AM; Ellis G; Tapper D
Am J Surg; 1991 May; 161(5):580-3. PubMed ID: 1674411
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma.
Pfisterer J; Kommoss F; Sauerbrei W; Rendl I; Kiechle M; Kleine W; Pfleiderer A
Gynecol Oncol; 1995 Aug; 58(2):149-56. PubMed ID: 7622098
[TBL] [Abstract][Full Text] [Related]
16. P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression.
Coronado PJ; Vidart JA; Lopez-asenjo JA; Fasero M; Furio-bacete V; Magrina J; Escudero M
Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):103-8. PubMed ID: 11516808
[TBL] [Abstract][Full Text] [Related]
17. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.
Levesque MA; Clark GM; Yu H; Diamandis EP
Br J Cancer; 1995 Sep; 72(3):720-7. PubMed ID: 7545416
[TBL] [Abstract][Full Text] [Related]
18. Role of DNA ploidy analysis in endometrial adenocarcinoma.
Jhala DN; Atkinson BF; Balsara GR; Hernandez E; Jhala NC
Ann Diagn Pathol; 2001 Oct; 5(5):267-73. PubMed ID: 11598854
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma.
Soong R; Knowles S; Williams KE; Hammond IG; Wysocki SJ; Iacopetta BJ
Br J Cancer; 1996 Aug; 74(4):562-7. PubMed ID: 8761370
[TBL] [Abstract][Full Text] [Related]
20. Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer.
Falcón O; Chirino R; León L; López-Bonilla A; Torres S; Fernández L; García-Hernández JA; Valerón PF; Díaz-Chico JC
Br J Cancer; 1999 Feb; 79(3-4):570-6. PubMed ID: 10027332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
